Join the discussion — anonymously
Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.
Comments (2)
The Lakeland situation is definitely the elephant in the room. I’ve seen the same pattern over the last few quarters; they prioritize the share price while ignoring the impact on the people actually doing the work. It’s impossible to feel secure when 'efficiency' is the only word being thrown around in leadership meetings. Honestly, it’s best to keep your resume updated and stay quiet until the call happens. The culture really isn't what it used to be, and it’s getting harder to ignore the signs.
I hear you, but let’s look at the broader picture here. Every major medtech player is tightening their belts right now to hit those Q1 targets. It isn't just us—it’s the reality of the current economic environment. While the messaging feels cold, the company is still positioned to lead the market, which is why I’m holding onto my position. Try not to let the rumor mill get to you; focus on your own projects and see what the actual guidance says next week before you start panicking.